The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.
The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.
The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback